Kvantify

🔥 Kvantify Secures €10M Seed Round 🔥 We’re excited to share that Kvantify has successfully closed a €10 million seed round. This milestone empowers us to advance quantum computing's potential, starting with life sciences. Led by Dreamcraft Ventures, Lundbeckfonden BioCapital, and 2degrees with participation from Redstone QAI Quantum Fund, 2xN, and EIFO this funding round strengthens our global position and accelerates the development of our groundbreaking solutions for drug discovery and beyond. Our CEO, Hans Henrik H. Knudsen, shares: "We believe the greatest potential in quantum computing, one that will create the first revolutionary impact, lies in discovering new and better medicines" We look forward to continue pioneering advancements in quantum computing software with a strong focus on on practical applications of quantum computing, starting with drug discovery and chemistry simulation. Read more at our website here (🇬🇧): https://lnkd.in/dmPhJTVg or in today’s Børsen here (🇩🇰): https://lnkd.in/dJ3-fZwP We are very grateful for all the people believing in us, with or without name. Dreamcraft Ventures | Lundbeckfonden / Lundbeck Foundation BioCapital | 2degrees | Redstone QAI Ventures | 2xN | Export and Investment Fund of Denmark

Minimising extra swap gates in quantum computing – an optimal and scalable solution. In quantum computing, adding optimal extra swap gates can be costly and complex, particularly when dealing with larger numbers of qubits. While various solutions have been suggested, they often lack two key features: scalability and optimality. A new paper addresses this issue, authored by our quantum research expert Irfansha Shaik, in collaboration with Professor Jaco van de Pol from Aarhus Universitet. Their work introduces a scalable solution to optimal layout synthesis for deep quantum circuits on NISQ processors with 100 qubits. Irfansha Shaik’s paper was awarded runner-up for Best Student Paper at The International Conference on Theory and Applications of Satisfiability Testing (SAT-2024). As a small spoiler, we can share that Irfansha has already had another paper accepted for the European Conference on Artificial Intelligence, 19-24 October in Santiago de Compostela, Spain (ECAI-2024). Read more about the findings here: https://lnkd.in/dwQ4TuFE And watch the video below to learn more about Irfansha 👇 #QuantumComputing #TechResearch #OptimalSolutions #QuantumInnovation #ScalableTechnology

Thank you to everyone who joined us at the Medicon Valley Alliance Good Morning Meeting last week! We had the pleasure of hosting more attendees than we had imagined, all of whom were eager to dive into the future of drug discovery. It was fantastic to explore how physics-based models and AI are accelerating drug development - reshaping the way we approach complex challenges. A special shoutout to Morten Allesø from Tetra Pharm Technologies for sharing valuable insights about their work in CNS and immune system-targeted therapies. Our collaboration together has opened up new possibilities, and it was great to hear how they are leveraging these novel tools in their research. The event also offered great networking opportunities, where peers exchanged experiences on computational drug discovery (CADD) and discussed emerging trends in pharmaceutical innovation. And remember, you’re always welcome to reach out if you’re curious about what we’re working on!

Greetings from Boston! We’re thrilled to have the opportunity to be here as part of the Nordic Mentor Network For Entrepreneurship - NOME delegation. It’s been a fantastic opportunity to connect with leading minds and innovative companies from the pharma and biotech industries. A big thank you to Jørn Emborg and Ann-Christina Lange from Innovation Centre Denmark Boston, Peter Birk from Nordic Mentor Network For Entrepreneurship - NOME and Accelerace, Novo Nordisk, along with other we've interacted with this week including MassBio, the Danish Minister of Industry, Business and Financial Affairs (Erhvervsministeriet), Morten Bødskov. A special shoutout to our fellow companies in the delegation, including Named Group, Aplex Bio, VEIL.AI, Inform Life, TRI, Accelerace and UIC - Uppsala Innovation Centre.

Quantum.Tech has kicked off, and we are lucky to have Ulrich Hoff and Rasmus Jarbøl in London, with the Danish delegation, to present Kvantify's advancements at the intersection of drug discovery, quantum chemistry, and quantum computing 🚀 Have a great day 2!

Last chance to sign up for our event with Medicon Valley Alliance (MVA) where you're invited! Join us this Thursday for our morning meeting in collaboration with MVA where we will deep dive into new methods in computational drug discovery. We will also talk about how physics-based models are transforming the landscape, speeding up drug development, and making AI in life sciences more powerful. And of course we'll have time for networking, coffee and a Q&A. Date: Thursday, 26th of September Time: 8:30 – 11:00 Where: Medicon Valley Alliance, Arne Jacobsens Allé 15, Hub 2, 2300, Copenhagen S Don't miss out on insights from Kvantify’s Hans Henrik H. Knudsen and Mikael Hvidtfeldt Christensen, along with experts Morten Allesø, Tetra Pharm Technologies and David Gloriam, Københavns Universitet - University of Copenhagen. The event is free - sign up now here: https://lnkd.in/dz92x5wC

🤔 Why physics-based models may be exactly what AI needs to succeed in Drug Discovery - Find out why... 👇 ...and much more in this blogpost by our Technical Product Manager, Mikael Hvidtfeldt Christensen: https://lnkd.in/dWG8ftSX ⌨️ "While AI won't replace lab experiments or human expertise any time soon, it has the potential to significantly enhance drug discovery. However, overcoming key challenges like data sparsity, lack of diversity, and inconsistencies in datasets is crucial. At Kvantify, we believe our physics-based models may offer a solution." #AI #DrugDiscovery #CADD #takethenextleap

Life sciences, and drug discovery in particular, is our key focus area. And we see a great potential in addressing and challenging today's methods for computational drug discovery, starting with our product, Koffee. Drug discovery is often a slow and costly process, with failure rates exceeding 90% and a timeline of more than 10 years for a drug to reach the market. In silico methods have already made strides, but there's potential for quantum and classical computing to unlock greater speed and precision, and with that better insights leading to better success rates. By combining classical and quantum computing, we can harness the strengths of both: classical methods for speed, quantum computing for precision. Our un-binding kinetics method is an example of how we've re-engineered classical methods to prepare for quantum algorithms, resulting in an advantage today, while pushing the boundaries of what’s possible in drug discovery. Koffee will not only accelerate the identification of drug candidates but also significantly improve the accuracy and efficiency of evaluating them. Read more here: https://lnkd.in/dZQZJF26 And watch the video below 👇

Hans Henrik H. Knudsen recently joined Paolo Cuomo on the Quantum London podcast for a deep dive into Kvantify. In the episode, Hans Henrik shares how Kvantify is developing innovative software applications and offering our services, based on computational excellence in both quantum and classical computing. A key focus of our work is in quantum chemistry and computer-aided drug discovery, as we believe that chemical simulation will be the first breakthrough application of quantum computing. Hans Henrik also highlighted our dual-focus strategy, where we seek to deeply understand business challenges to develop software and solutions that provide immediate value, while pushing the quantum computing technology forward. Listen to the full episode to learn more about quantum technology and its transformative potential in life sciences: https://lnkd.in/dfCrnMZN Also, we will be at the Quantum London conference the 23rd of September - feel free to reach out if you're also participating!

Did you know our product, Koffee, can transform your drug discovery process? Here’s how 👇 Predict Unbinding Kinetics: Koffee offers a novel method to accurately predict k-off rates, a key metric that indicates how long a drug interacts with its target—crucial information for effective dosing. Faster and More Accurate: Unlike traditional methods such as molecular dynamics (MD), that are slow and complex, Koffee provides rapid and precise predictions with fully automated setup, ideal for higher throughput screening. Unmatched Market Alternative: Currently, many pharma and biotech companies only measure unbinding kinetics for advanced molecules, or not at all due to the complexity, cost, and lengthy timelines. Koffee fills this gap with a straightforward solution. Extensive Benchmarking: We’ve validated Koffee across more than a dozen targets and hundreds of ligands, including critical drug targets like kinases, GPCRs, and molecular chaperones. With results showing excellent correlation with experimental data. Data-Driven Optimization: With Koffee, the selection and optimization of drug candidates based on kinetic properties become data-driven, allowing you to de-risk the drug discovery process and make informed decisions earlier. Learn more about Koffee in the video below or here: https://lnkd.in/dZQZJF26